SG3 Management’s Teva Pharmaceuticals TEVA Stock Holding History

SG3 Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16,350	Closed	-$123K	–	434
2022 Q2	$123K	Sell	16,350 -68,650	-81%	-$598K	0.01%	307
2022 Q1	$798K	Sell	85,000 -127,000	-60%	-$1.06M	0.02%	504
2021 Q4	$1.7M	Buy	212,000 +52,000	+33%	+$469K	0.03%	370
2021 Q3	$1.56M	Hold	160,000	–	–	0.05%	355
2021 Q2	$1.58M	Sell	160,000 -30,000	-16%	-$318K	0.06%	364
2021 Q1	$2.19M	Buy	190,000 +39,700	+26%	+$455K	0.05%	380
2020 Q4	$1.45M	Buy	150,300 +70,300	+88%	+$673K	0.03%	466
2020 Q3	$721K	Sell	80,000 -20,000	-20%	-$212K	0.03%	487
2020 Q2	$1.23M	Buy	+100,000	New	+$1.13M	0.09%	254
2019 Q2	–	Sell	-10,000	Closed	-$157K	–	518
2019 Q1	$157K	Hold	10,000	–	–	0.02%	241
2018 Q4	$154K	Buy	+10,000	New	+$205K	0.04%	157

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

SG3 Management's TEVA Position: Q3 2022 in Review

SG3 Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 16,350 shares — an estimated $123K sold.

SG3 Management first reported a position in TEVA in Q4 2018 and held it in 11 quarters. The position peaked at $2.19M in Q1 2021. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

SG3 Management reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
SG3 Management sold 16,350 Teva Pharmaceuticals shares in Q3 2022, an estimated $123K.
SG3 Management first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 11 quarters.
SG3 Management's Teva Pharmaceuticals position peaked at $2.19M in Q1 2021.
430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.